Biosimilar Monoclonal Antibodies

monoclonal antibody (mAb) is originally produced by a single B-cell. Biosimilars are a lot complicated than small-molecule medicine and generics. In the past few years, monoclonal antibody drugs have dominated the world's largest biopharmaceutical drug sales, and in the coming years, monoclonal antibody drugs will continue to be the main force. Considering the huge profit margins and potential market, the monoclonal antibody-based therapeutics is the hot territory many pharmaceutical companies chases. This session will summarize the market in terms of therapeutic applications, type, and structure of mAbs, dominant companies, manufacturing locations, and emerging markets. These requirements would lead to greater development in the process and tighter quality controls during the production of biosimilar mAbs.

  • FDA-approved mAb drugs
  • Monoclonal antibody therapy
  • Anti-Cancer Antibodies
  • Cancer Immune therapy
  • Antibody Humanization Technologies
  • Biotherapeutics : Early Analytical Development

Related Conference of Biosimilar Monoclonal Antibodies

Biosimilar Monoclonal Antibodies Conference Speakers